Fourth dose of BNT162b2 prevents severe COVID-19 in nursing home residents
Jun 27, 2022
Substantial protection against hospitalizations and deaths seen among nursing home residents during the omicron surge.
Protection against omicron strongest with hybrid immunity
Jun 17, 2022
Immunity resulting from previous COVID-19 infection and recent booster vaccination confers the strongest protection against the omicron infection.
Veterans report low rates of adverse events with mRNA vaccines
Jun 16, 2022
Rates were slightly higher at 42 days for those receiving the Pfizer versus Moderna vaccine.
COVID-19 vaccines cut mortality with heart failure
Jun 16, 2022
Those who are partially vaccinated and unvaccinated face the same increased risk, whereas boosted and fully vaccinated adults fare best.
Vaccine effectiveness against SARS-CoV-2 infection wanes over time
Jun 14, 2022
However, for all ages, vaccine effectiveness against severe COVID-19 was high overall, at 90% five months or longer after two doses.
Vaccination offers partial protection for postacute phase of COVID-19
May 31, 2022
Individuals with breakthrough infection have an increased risk for death and postacute sequelae compared with contemporary controls.
Plant-based recombinant COVID-19 vaccine found to be effective
May 04, 2022
Vaccine efficacy ranged from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Single dose of AZD7442 effectively prevents COVID-19
Apr 22, 2022
A relative risk reduction of 82.8% was seen in symptomatic COVID-19 at extended follow-up of a median of six months.
Early effectiveness assessed for fourth dose of BNT162b2 vaccine
Apr 21, 2022
The difference in absolute risk for three versus four doses was 180.1 and 68.8 cases per 100,000 for COVID-19-related hospitalization and severe COVID-19.
Overall risk of myopericarditis low after COVID-19 vaccine
Apr 12, 2022
The overall incidence of myopericarditis does not differ significantly for those receiving COVID-19 vaccines versus non-COVID-19 vaccines.